posted on 2016-02-05, 15:58authored byGuanglin Luo, Ling Chen, Catherine R. Burton, Hong Xiao, Prasanna Sivaprakasam, Carol M. Krause, Yang Cao, Nengyin Liu, Jonathan Lippy, Wendy
J. Clarke, Kimberly Snow, Joseph Raybon, Vinod Arora, Matt Pokross, Kevin Kish, Hal A. Lewis, David R. Langley, John E. Macor, Gene M. Dubowchik
GSK-3
is a serine/threonine kinase that has numerous substrates.
Many of these proteins are involved in the regulation of diverse cellular
functions, including metabolism, differentiation, proliferation, and
apoptosis. Inhibition of GSK-3 may be useful in treating a number
of diseases including Alzheimer’s disease (AD), type II diabetes,
mood disorders, and some cancers, but the approach poses significant
challenges. Here, we present a class of isonicotinamides that are
potent, highly kinase-selective GSK-3 inhibitors, the members of which
demonstrated oral activity in a triple-transgenic mouse model of AD.
The remarkably high kinase selectivity and straightforward synthesis
of these compounds bode well for their further exploration as tool
compounds and therapeutics.